Bibliography
- Arias C, Murray B. Antibiotic-resistant bugs in the 21st century – a clinical super challenge. N Engl J Med 2009;360:439-43
- Klein E, Smith D, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States 1999-2005. Emerg Infect Dis 2007;13:1840-6
- Boucher H, Talbot G, Bradley J, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 2009;48:1-12
- Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109
- Payne D, Gwynn M, Holmes D, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Dis 2007;6:29-40
- Collin F, Karkare S, Maxwell A. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 2011;92:479-97
- Sissi C, Palumbo M. In front of and behind the replication fork: bacterial type IIa topoisomerases. Cell Mol Life Sci 2010;67:2001-24
- Lambert HP, O’Grady FW. editors. Coumarins. Churchill Livingstone; Edinburgh: 1992
- Boehm H, Boehringer M, Bur D, et al. Novel inhibitors of DNA gyrase: 3D structure biased needle screening hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000;43:2664-74
- Lubbers T, Angehrn P, Gmunder H, et al. Design, synthesis and structure-activity relationship studies of ATP analogs as DNA gyrase inhibitors. Bioorg Med Chem Lett 2000;10:821-6
- Oblak M, Kotnik M, Solmajer T. Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 2007;14:2033-47
- Vertex Pharmaceuticals.Gyrase. Inhibitors and Uses Thereof 2012. WO2002060879
- Mani N, Gross C, Parsons J, et al. In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 2006;50:1228-37
- Grossman T, Bartels D, Mullin S, et al. Dual targeting of GyrB and ParE by a novel Aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 2007;51:657-66
- Charifson P, Grillot A, Grossman T, et al. Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 2008;51:5243-63
- Silver L. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Dis 2007;6:41-55
- Vertex Pharmaceuticals. Pyrimidine gyrase and topoisomerase IV inhibitors 2012. WO2012097269
- Vertex Pharmaceuticals. Phosphate esters of gyrase and topoisomerase inhibitors 2012. WO2012177707
- Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Dis 2008;7:255-70
- Im WB, Choi SH, Park JY, et al. Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011;46:1027-39
- Baker W, Cai S, Dimitroff M, et al. A prodrug approach toward the development of water soluble fluoroquinolones and structure−activity relationships of quinoline-3-carboxylic acids. J Med Chem 2004;47:4693-709
- Vertex Pharmaceuticals. Process for making gyrase and topoisomerase IV inhibitors 2012. WO2012097274
- Vertex Pharmaceuticals. Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[ 2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl] -7-(tetrahydrofuran-2-yl)- 1H-benzimidazol-2-yl]urea 2012. WO2012097273